Perilesional Targeted Biopsy Combined with MRI-TRUS Image Fusion-Guided Targeted Prostate Biopsy: An Analysis According to PI-RADS Scores.
Masayuki TomiokaKensaku SeikeHiromi UnoNami AsanoHaruo WatanabeRisa Tomioka-InagawaMakoto KawaseDaiki KatoManabu TakaiKoji IinumaYuki TobisawaKeita NakaneKunihiro TsuchiyaTakayasu ItoTakuya KoiePublished in: Diagnostics (Basel, Switzerland) (2023)
A prostate-targeted biopsy (TB) core is usually collected from a site where magnetic resonance imaging (MRI) indicates possible cancer. However, the extent of the lesion is difficult to accurately predict using MRI or TB alone. Therefore, we performed several biopsies around the TB site (perilesional [p] TB) and analyzed the association between the positive cores obtained using TB and pTB and the Prostate Imaging Reporting and Data System (PI-RADS) scores. This retrospective study included patients who underwent prostate biopsies. The extent of pTB was defined as the area within 10 mm of a TB site. A total of 162 eligible patients were enrolled. Prostate cancer (PCa) was diagnosed in 75.2% of patients undergoing TB, with a positivity rate of 50.7% for a PI-RADS score of 3, 95.8% for a PI-RADS score of 4, and 100% for a PI-RADS score of 5. Patients diagnosed with PCa according to both TB and pTB had significantly higher positivity rates for PI-RADS scores of 4 and 5 than for a PI-RADS score of 3 ( p < 0.0001 and p = 0.0009, respectively). Additional pTB may be performed in patients with PI-RADS ≥ 4 regions of interest for assessing PCa malignancy.
Keyphrases
- prostate cancer
- magnetic resonance imaging
- mycobacterium tuberculosis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- patients undergoing
- prognostic factors
- contrast enhanced
- computed tomography
- ultrasound guided
- high resolution
- drug delivery
- deep learning
- young adults
- photodynamic therapy
- magnetic resonance